IBD therapeutics have entered a multi-mechanism era, with selective IL-23 inhibitors (risankizumab, mirikizumab), the S1P receptor modulator etrasimod, and the JAK1-selective upadacitinib joining established anti-TNFs and vedolizumab.
Hepatology in 2027 is defined by the first FDA-approved MASH therapy — resmetirom (THR-beta agonist) following MAESTRO-NASH — and the rapid expansion of GLP-1 and dual agonists (semaglutide ESSENCE, survodutide, tirzepatide) into metabolic liver disease.
Third-space endoscopy has matured into a discipline of its own, with endoscopic submucosal dissection (ESD) increasingly preferred over EMR for high-risk early GI neoplasia and POEM established as a durable achalasia therapy.
GI oncology is being reshaped by molecularly stratified care: ctDNA-guided adjuvant decisions in stage II/III colon cancer (DYNAMIC, GALAXY), MSI-high tumors responding to neoadjuvant dostarlimab and pembrolizumab (with watch-and-wait emerging in rectal cancer), and HER2-positive gastric/GEJ disease driven by trastuzumab deruxtecan and zolbetuximab (CLDN18.2).
Disorders of gut-brain interaction are being reframed by Rome IV, high-resolution manometry, and the wireless motility capsule.
Microbiota therapeutics have transitioned from investigational FMT into FDA-approved live biotherapeutic products: Rebyota (RBL-2660) and Vowst (SER-109) for prevention of recurrent C.
Pediatric GI is increasingly aligned with adult therapeutic advances while preserving developmental and growth-specific endpoints.
Nutrition support in 2027 emphasizes early enteral feeding in critical illness, ESPEN-aligned protein targets, and structured home parenteral nutrition programs with teduglutide for intestinal failure.
AI is now embedded in routine endoscopy, with CADe systems (GI Genius, ENDO-AID, CAD EYE) demonstrating consistent adenoma detection rate (ADR) gains in randomized trials and real-world registries.
EoE management has shifted dramatically with dupilumab approval and growing recognition of disease heterogeneity.
Upper-GI cancers represent significant global mortality with major treatment-paradigm shifts in immunotherapy and screening.
Pancreatic conditions span acute pancreatitis to pancreatic cancer with major diagnostic and therapeutic advances.
Surgical and interventional biliary disease care intersects gastroenterology, surgery and interventional radiology.
Therapeutic endoscopy expands rapidly with new tools, techniques and credentialing pathways.
Endoscopic bariatric procedures offer a non-surgical option for obesity treatment with growing evidence base.
MASH management has been transformed by resmetirom approval.
Hepatitis C treatment success and ongoing HBV/HDV pipeline define this field with WHO 2030 elimination targets driving policy.
Upper and lower GI bleeding remain emergencies with evolving management protocols.
Diverticular disease management has evolved beyond antibiotics-for-all with growing evidence-based pathways.
Colorectal cancer screening has moved to age 45 with new modalities and quality measures expanding.
Helicobacter pylori management is shaped by rising antimicrobial resistance and the new vonoprazan era.
GERD management spans lifestyle modification to surgical intervention with new pharmacological options.
Esophageal and intestinal motility disorders benefit from high-resolution manometry, new pharmacotherapy and endoscopic interventions.
Anorectal disorders affect quality of life significantly and require specialised diagnostic and treatment approaches.
Small bowel disease has been transformed by video capsule endoscopy and balloon enteroscopy.
Mesenteric ischemia and vascular GI disorders are uncommon but carry significant morbidity and require multidisciplinary care.
Disorders of gut-brain interaction (DGBI) require central and gut-targeted approaches with growing pharmacotherapy options.
GI manifestations of cystic fibrosis are increasingly important as patients live longer with CFTR modulator therapy.
Geriatric GI care addresses age-specific presentations and risks with the rising elderly population.
Sex-specific GI conditions and management considerations.
Tropical and parasitic GI diseases remain significant globally with growing importance in travel medicine and immigration health.
Liver transplant indications, allocation and outcomes are evolving with MELD 3.0, machine perfusion and emerging donor expansion.
Advanced GI imaging spans CT, MRI, ultrasound and emerging modalities with AI augmentation.
Video capsule endoscopy has expanded beyond small bowel to colon and oesophagus with AI-augmented reading platforms.
Disparities in GI care outcomes are significant and require systematic intervention.